Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

How Does Coronavirus Turn Our Immune System Against Us?

How Does Coronavirus Turn Our Immune System Against Us?

New scientific evidence suggests that a history of age-related macular degeneration (an eye condition also known as yellow spot disease), thrombocytopenia (a low blood platelet count), thrombosis (a clotting problem) or bleeding is associated with COVID-19 in terms of both a higher risk of developing the disease and a higher risk of dying from it.

The findings come from research on specific cellular pathways that make COVID-19 more severe and cause "immune system dysregulation". A deeper look at the mechanisms behind poorer clinical outcomes points to differences in the complement and coagulation components of the immune system. Both complement and coagulation components are associated with inflammation.

The complement (complementary) system is a biochemical pathway that helps clear pathogens from an organism and is considered part of the immune system. It contains a small amount of proteins that are inactive in the blood. When stimulated by certain triggers, they become active to induce the release of cytokines, the immune system's messenger molecules. Activation of the complement system activates the cell-killing surface attack complex. The novel coronavirus (SARS-CoV-2) is thought to turn our immune system against our own cells through complement activation.

Study author Sagi Shapira, a systems biology researcher (in microbiology and immunology) at Columbia University in New York City, said: “In this case, SARS-CoV-2 appears to use the complement and coagulation systems, about whose molecular details we have at least some clues and on which we are actively working, to turn our immune system against us."

This valuable study was published on August 3 in Nature Medicine.

In a retrospective observational study, researchers evaluated 11,116 patients with suspected SARS-CoV-2 infection. These patients had presented to NewYork-Presbyterian / Columbia University Irving Medical Center between February 1 and April 25. A total of 6398 (58%) tested positive for coronavirus.

The participants' mean age was 52, and 45% were male. Around 27% had coronary artery disease, 13% had type 2 diabetes and 12% were obese. A total of 88 patients had a history of macular degeneration, 4 had a complement deficiency disorder and 1179 had a coagulation disorder. The researchers considered a history of macular degeneration a biomarker for complement activation disorders.

Key findings

  • Risks associated with macular degeneration and coagulation disorders, including mechanical ventilation and death, were independent of age, sex or smoking history.
  • The researchers said, "In particular, we found no evidence that smoking status (past or present) was a significant risk factor for mechanical ventilation or death".
  • Among participants with a history of macular degeneration, 14 patients were intubated and 22 died.
  • Shapira and colleagues also performed transcriptional genetic profiling. This analysis revealed type-1 interferon- and interleukin-6-mediated inflammatory responses involved in complement and coagulation pathways.
  • The researchers also identified candidate genetic variants (changes) in these pathways associated with more severe COVID-19 infection.

Let us look at the bigger picture

This is not the first study linking dysregulation and genetic variation in complement and coagulation pathways to viral infection. For example, similar findings in dengue virus infection are also associated with more severe disease. The authors suggest that this indicates that "complement and coagulation dysfunction may represent risk factors for a broad range of pathogens."

Shapira said, "More broadly, I think we are poised to use the framework we have developed by combining structural biology, analytical approaches to electronic health records and genomics to uncover the basic biology and underlying pathophysiology contributing to morbidity (illness) and mortality (death) associated with other infectious diseases".

Shapira cautioned that, despite the progress, it was still too early to change clinical practice. "Although there are clues that existing treatments targeting complement and coagulation could be promising for COVID-19 patients, these studies are at an early stage. Unfortunately, we are not at the point where these results should affect the standard supportive care currently being given."

Our greatest strength against COVID-19 remains prevention. Wearing masks, washing hands, and rapidly identifying and isolating people who are ill or suspected of being ill... Also, be aware of your patients' comorbidities, lifestyles and whether they are obese; talk to them and encourage those with important risk factors, including coagulation and complement dysfunction, to be particularly careful.

Shapira said, "After becoming infected with SARS-CoV-2, patients with a history of complement and coagulation disorders may be good candidates for immunotherapies.".

Shapira said that clinical trials were investigating the therapeutic (treatment) potential of existing drugs targeting complement and coagulation pathways, adding, "We cannot wait to see whether we can turn what we have learned into valuable treatment.".

Complementary findings

Asked to comment on the study, Benjamin tenOever, professor of microbiology at the Icahn School of Medicine at Mount Sinai in New York City, said, "I do not find targeting the coagulation and complement system particularly effective".

On May 28, Cell published research on imbalanced host responses associated with COVID-19 development. A host is an organism that harbors another organism as a parasite within or on itself, or an animal or human within or on which a disease-causing organism feeds. As the study's senior author, tenOever added, "All these findings were reported long before this publication. We have known about the complement and coagulation system in response to SARS-CoV-2 since May."

Shapira said that although the peer-reviewed Nature Medicine paper was published on August 3, a preprint of the study had appeared in early May. He also noted that the role of complement and coagulation functions in coronavirus infections had been understood "long before this pandemic began" in small animal studies and human research investigating SARS-1 and MERS infections.

Sources

2. Vijendra Ramlall, Sagi D. Shapira et al.
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection.
Nature Medicine, 03 August 2020.

1. More Clues on How COVID-19 Can Turn Immune System Against Us - Medscape - Aug 25, 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

How Does Coronavirus Turn Our Immune System Against Us?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy